CAS 84449-90-1
:Raloxifène
- [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
- Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-
- Raloxifene
- Keoxifene
- LY 139481
Raloxifene Hydrochloride
CAS :Formule :C28H27NO4S·HClDegré de pureté :>98.0%(T)(HPLC)Couleur et forme :Light yellow to Yellow to Green powder to crystalMasse moléculaire :510.05Raloxifene
CAS :Raloxifene (LY139481) is an estrogen receptor modulator exhibiting estrogen agonist and antagonist activity at different sites, with antiviral activity.Formule :C28H27NO4SDegré de pureté :99.39%Couleur et forme :Light-Yellow SolidMasse moléculaire :473.58Ref: TM-T20419
2mg39,00€5mg58,00€10mg92,00€25mg177,00€50mg264,00€100mg391,00€200mg567,00€1mL*10mM (DMSO)62,00€Raloxifene
CAS :Produit contrôléApplications Raloxifene is a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
References Jone, C.D., et al.: J. Med. Chem., 27, 1057 (1984); Buelke-Sam, J., et al.: Reprod. Toxicol., 12, 217 (1998)Formule :C28H27NO4SCouleur et forme :Off White SolidMasse moléculaire :473.582-(4-hydroxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]benzoyl}-1-benzothiophen-6-ol
CAS :Formule :C28H27NO4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :473.5833Raloxifene
CAS :Produit contrôléRaloxifene is a non-steroidal drug that binds to estrogen receptors, which may be useful in the treatment of postmenopausal osteoporosis. Raloxifene has been shown to increase bone mineral density and reduce the risk of vertebral fractures in postmenopausal women with osteoporosis. Raloxifene also has been found to decrease breast cancer risk by about 50% in postmenopausal women. The drug binds to estrogen receptors in breast tissue, preventing the stimulation of these cells by estrogen and decreasing their growth rate. Raloxifene also inhibits the production of lactogenic hormones such as prolactin and progesterone that are involved in breast cancer development. Raloxifene hydrochloride is used at doses between 60 mg and 120 mg per day for a duration of 5 years.
Raloxifene hydrochloride is not active against estrogen receptor positive tumors and should not be used for treatment of breast cancer.Formule :C28H27NO4SDegré de pureté :Min. 95%Couleur et forme :PowderMasse moléculaire :473.58 g/molRef: 3D-FR175031
Produit arrêté





